Imigran

Sumatriptan, the active ingredient in Imigran, is a triptan presented as a 20 mg nasal spray for nasal use. It treats acute migraine attacks with or without aura in adults.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan) is indicated for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine with aura: provides rapid relief of headache and associated neurological symptoms. - Migraine without aura: reduces headache intensity and duration when taken early in an attack. - Migraine when oral administration is not feasible: nasal spray offers an alternative route for quick absorption and symptom control.

Common Side Effects: - Nasal irritation or burning sensation. - Unpleasant taste or metallic taste. - Dizziness or light‑headedness. - Somnolence or mild fatigue. - Nausea or mild stomach upset. - Throat irritation.

Serious or Rare Side Effects: - Chest pain or tightness suggesting coronary vasospasm. - Severe hypertension or hypertensive crisis. - Serotonin syndrome, especially with other serotonergic agents. - Allergic reactions including rash, angioedema, or anaphylaxis. - Ischemic events such as myocardial infarction or stroke. - Severe arrhythmias or cardiac rhythm disturbances.

Imigran should be used with caution in patients with certain medical conditions and in specific situations.

- Cardiovascular disease: avoid use in patients with known coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. - Serotonergic agents: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, MAO inhibitors, or other triptans. - Pregnancy: safety not established; use only if potential benefit justifies potential risk to the fetus. - Elderly patients: start with the lowest effective dose and monitor for adverse reactions. - Drug interactions: review all concomitant medications for possible interactions before prescribing. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - MAO inhibitors (e.g., phenelzine, tranylcypromine): risk of severe hypertension. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: potential for serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): heightened risk of hypertensive reactions.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may require dose adjustment due to vasoconstriction. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase sumatriptan plasma levels. - Oral contraceptives: monitor for increased migraine frequency or severity.